Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

NCT05267886 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT05267886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 4
Overall status
Recruiting
Start date
March 5, 2022
Completion date
December 31, 2026
Enrollment
346 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

shock, cardiogenic